Einzeltreffer — DigiBib

Introduction: Brain neoplasms and central nervous system (CNS) disorders, particularly gliomas, have shown a notable increase in incidence over the last three decades, posing significant diagnostic and therapeutic challenges. MicroRNAs (miRNAs) have emerged as promising biomarkers due to their regulatory role in gene expression, offering potential enhancements in glioma diagnosis and prognosis.

Methods: This systematic review and meta-analysis, adhering to PRISMA guidelines, included 25 studies for diagnostic accuracy and 99 for prognostic analysis, published until August 27th, 2023. Studies were identified through comprehensive searches of PubMed, Web of Science, and Scopus databases. Inclusion criteria encompassed peer-reviewed original research providing sensitivity, specificity, and area under the curve (AUC) for miRNAs in glioma diagnosis, as well as survival outcomes with hazard ratios (HRs) or mean survival.

Results and Discussion: Meta-analysis demonstrated miRNAs' high diagnostic accuracy, with a pooled sensitivity of 0.821 (95% CI: 0.781-0.855) and specificity of 0.831 (95% CI: 0.792-0.865), yielding an AUC of 0.893. Subgroup analysis by specimen type revealed consistent accuracy across blood, cerebrospinal fluid (CSF), and tissue samples. Our results also showed miRNAs can be potential prognostic biomarkers. miRNAs showed significant associations with overall survival (OS) (pooled HR: 2.0221; 95% CI: 1.8497-2.2105), progression-free survival (PFS) (pooled HR: 2.4248; 95% CI: 1.8888-3.1128), and disease-free survival (DFS) (pooled HR: 1.8973; 95% CI: 1.1637-3.0933) in tissue specimens. These findings underscore miRNAs' potential as valuable biomarkers for improving glioma diagnosis and prognosis, offering insights for enhancing clinical decision-making and patient outcomes.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Titel:	MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis.
Autor/in / Beteiligte Person:	Hasani, F ; Masrour, M ; Jazi, K ; Ahmadi, P ; Hosseini, SS ; Lu, VM ; Alborzi, A
Zeitschrift:	Frontiers in neurology, Jg. 15 (2024-02-29), S. 1357321
Veröffentlichung:	[Lausanne : Frontiers Research Foundation, 2010]-, 2024
Medientyp:	unknown
ISSN:	1664-2295 (print)
DOI:	10.3389/fneur.2024.1357321
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Systematic Review Language: English [Front Neurol] 2024 Feb 29; Vol. 15, pp. 1357321. <i>Date of Electronic Publication: </i>2024 Feb 29 (<i>Print Publication: </i>2024). References: Mol Genet Genomics. 2022 Mar;297(2):357-371. (PMID: 35064290) ; J Neurol Sci. 2015 Jan 15;348(1-2):181-7. (PMID: 25510379) ; Biomark Res. 2021 Mar 12;9(1):18. (PMID: 33712063) ; World Neurosurg. 2019 May;125:e1217-e1225. (PMID: 30794970) ; Mol Cell Biol. 2008 Sep;28(17):5369-80. (PMID: 18591254) ; Nat Struct Mol Biol. 2015 Jan;22(1):20-8. (PMID: 25565029) ; Psychometrika. 2015 Dec;80(4):1084-104. (PMID: 25361619) ; J Clin Neurosci. 2014 May;21(5):755-60. (PMID: 24382515) ; Lung Cancer. 2019 Jun;132:99-106. (PMID: 31097102) ; Apoptosis. 2019 Aug;24(7-8):662-672. (PMID: 31134446) ; PLoS Med. 2009 Jul 21;6(7):e1000097. (PMID: 19621072) ; Med Sci Monit. 2014 Dec 07;20:2571-7. (PMID: 25481483) ; Nat Rev Dis Primers. 2015 Jul 16;1:15017. (PMID: 27188790) ; Evid Based Ment Health. 2019 Nov;22(4):153-160. (PMID: 31563865) ; Int J Clin Exp Pathol. 2019 Jul 01;12(7):2536-2543. (PMID: 31934080) ; Brain Behav. 2018 Feb 19;8(4):e00941. (PMID: 29670823) ; Int J Clin Exp Pathol. 2015 May 01;8(5):4943-52. (PMID: 26191187) ; Oncol Lett. 2016 Jan;11(1):904-908. (PMID: 26870304) ; Oncol Lett. 2018 May;15(5):7215-7220. (PMID: 29849790) ; J Neurooncol. 2018 Jan;136(1):51-62. (PMID: 29076001) ; Oncol Lett. 2020 Mar;19(3):1967-1974. (PMID: 32194691) ; Diagn Pathol. 2013 Dec 10;8:200. (PMID: 24326156) ; BMC Med Res Methodol. 2014 Apr 01;14:45. (PMID: 24690082) ; Sci Rep. 2020 Mar 6;10(1):4220. (PMID: 32144351) ; Neuro Oncol. 2015 Mar;17(3):383-91. (PMID: 25140035) ; Cancers (Basel). 2019 Oct 12;11(10):. (PMID: 31614872) ; CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) ; Oncol Lett. 2019 Nov;18(5):4882-4890. (PMID: 31611998) ; J Neurooncol. 2017 Aug;134(1):241-242. (PMID: 28547591) ; J Neurooncol. 2017 Sep;134(3):505-512. (PMID: 28233083) ; Semin Liver Dis. 2015 Feb;35(1):3-11. (PMID: 25632930) ; J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. (PMID: 29118226) ; Cancer Control. 2019 Jan-Dec;26(1):1073274819847226. (PMID: 31046428) ; Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14879-84. (PMID: 18812516) ; Int J Clin Exp Med. 2015 Jan 15;8(1):456-63. (PMID: 25785017) ; J Clin Epidemiol. 2005 Oct;58(10):982-90. (PMID: 16168343) ; J Clin Neurosci. 2016 Jul;29:59-63. (PMID: 26988656) ; J Neurooncol. 2009 Jul;93(3):325-32. (PMID: 19159078) ; Nat Commun. 2017 Jun 19;8:15870. (PMID: 28627514) ; Brain Pathol. 2010 May;20(3):539-50. (PMID: 19775293) ; Biomed Res Int. 2020 Sep 25;2020:4689689. (PMID: 33029509) ; Neurol Sci. 2015 Feb;36(2):309-13. (PMID: 25190548) ; Ther Adv Med Oncol. 2021 Jan 31;13:1758835920987650. (PMID: 33613699) ; Cancer Biother Radiopharm. 2015 May;30(4):169-73. (PMID: 25811315) ; Mol Med Rep. 2018 Jan;17(1):322-329. (PMID: 29115595) ; Clin Neurol Neurosurg. 2019 Jan;176:103-109. (PMID: 30554090) ; PLoS One. 2013 Nov 12;8(11):e79467. (PMID: 24265774) ; Br J Cancer. 2015 Mar 31;112(7):1241-6. (PMID: 25756397) ; Cancers (Basel). 2022 Jul 18;14(14):. (PMID: 35884554) ; J Neurooncol. 2016 Oct;130(1):11-17. (PMID: 27531352) ; Biosci Rep. 2020 Jul 31;40(7):. (PMID: 32639004) ; Biomed Res Int. 2019 Mar 26;2019:4015969. (PMID: 31032345) ; J Biol Chem. 2012 Dec 28;287(53):44761-71. (PMID: 23148210) ; Front Cell Dev Biol. 2021 Jun 01;9:671202. (PMID: 34141710) ; Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. (PMID: 31675094) ; Front Oncol. 2022 May 12;12:898537. (PMID: 35646622) ; Neurol Sci. 2017 Jun;38(6):1087-1092. (PMID: 28367610) ; Nat Rev Genet. 2011 Feb;12(2):99-110. (PMID: 21245828) ; Radiology. 1982 Apr;143(1):29-36. (PMID: 7063747) ; Mol Cancer. 2012 Jul 02;11:44. (PMID: 22747855) ; Clin Chem. 2004 Jul;50(7):1118-25. (PMID: 15142978) ; Med Sci Monit. 2016 Mar 15;22:855-62. (PMID: 26978735) ; Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. (PMID: 36196752) ; Toxicol Rep. 2020 Nov 06;7:1514-1530. (PMID: 33251119) ; Cancer Biomark. 2017;19(2):137-144. (PMID: 28211798) ; Cancers (Basel). 2013 Oct 23;5(4):1306-31. (PMID: 24202447) ; J Neurosurg. 2016 Jan;124(1):122-8. (PMID: 26230475) ; J Exp Clin Cancer Res. 2012 Nov 22;31:97. (PMID: 23174013) ; Front Neurol. 2021 Feb 01;11:610163. (PMID: 33597912) ; Transl Oncol. 2022 Aug;22:101451. (PMID: 35598381) ; Cell Oncol (Dordr). 2018 Feb;41(1):25-33. (PMID: 29076027) ; CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525) ; Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4885-4890. (PMID: 27981547) ; Vet Comp Oncol. 2018 Jun;16(2):288-296. (PMID: 29314614) ; Cell. 2004 Jan 23;116(2):281-97. (PMID: 14744438) ; JAMA Netw Open. 2019 Dec 2;2(12):e1916953. (PMID: 31808923) ; Neuro Oncol. 2012 Jan;14(1):29-33. (PMID: 21937590) ; CNS Neurosci Ther. 2012 Jul;18(7):573-83. (PMID: 22630347) ; BMC Bioinformatics. 2014;15 Suppl 7:S4. (PMID: 25077573) ; PLoS One. 2018 Feb 14;13(2):e0189452. (PMID: 29444091) ; PLoS One. 2014 Oct 03;9(10):e108950. (PMID: 25279461) Contributed Indexing: Keywords: MicroRNAs; brain neoplasms; diagnosis; glioma; prognosis Entry Date(s): Date Created: 20240315 Latest Revision: 20240316 Update Code: 20240316 PubMed Central ID: PMC10937740

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis.